Results 81 to 90 of about 5,304 (170)
Sepsis is one of the most prevalent diseases in the world. The development of cardiac dysfunction in sepsis results in an increase of mortality. It is known that Bruton's tyrosine kinase (BTK) plays a role in toll-like receptor signaling and NLRP3 ...
Caroline E. O'Riordan +14 more
doaj +1 more source
Aim: Bruton’s tyrosine kinase inhibitors (BTKis), including ibrutinib and acalabrutinib, transformed the treatment landscape of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) by improving outcomes compared with ...
Lindsey Fitzgerald +9 more
doaj +1 more source
Introduction Bruton tyrosine kinase inhibitor (BTKi) monotherapies have improved patient outcomes in B cell lymphomas; however, evidence on their comparative efficacy remains limited.
Pier Luigi Zinzani +9 more
doaj +1 more source
Aim: To estimate cost savings associated with covalent Bruton’s tyrosine kinase inhibitor (cBTKi) choice in patients with treatment-naive (TN) and relapsed/refractory (RR) chronic lymphocytic leukemia (CLL) from a Medicare perspective.
Adam S Kittai +6 more
doaj +1 more source
Mantle cell lymphoma (MCL) is a rare and often aggressive type of non-Hodgkin lymphoma that predominantly affects older adults and presents significant treatment challenges due to its clinical complexity and poor prognosis.
Adrian Schmidt
doaj +1 more source
Supplementary Table S1. Kinase selectivity of acalabrutinib as assessed by DiscoveRX KinomeScan screening.
Carsten U. Niemann (14998799) +19 more
core +1 more source
Process for the Preparation of Crystalline Acalabrutinib Maleate Monohydrate [PDF]
Process for the Preparation of Crystalline Acalabrutinib Maleate Monohydrate Acalabrutinib or 4-{8-Amino-3-[(2S)-1-(but-2-ynoyl)pyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1- yl}-N-(pyridin-2-yl)benzamide is the active pharmaceutical ingredient (API) in the ...
Anonymous,
core +1 more source
Ibrutinib and acalabrutinib are both associated with an increased risk of atrial fibrillation (AF); however, the comparative risk of AF between these 2 BTK inhibitors remains largely unknown.
Joachim Alexandre +11 more
doaj +1 more source
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: Pooled analysis of 5 clinical trials [PDF]
: Before targeted therapies, patients with higher-risk chronic lymphocytic leukemia (CLL) defined as del(17p) and/or TP53 mutation (TP53m), unmutated immunoglobulin heavy chain variable region genes (uIGHV), or complex karyotype (CK) had poorer prognosis
Siddiqi, Tanya +11 more
core +1 more source

